

Universal Biosensors Inc
ARBN 121 559 993

1 Corporate Avenue
Rowville VIC 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

14 May 2015

Siemens announces full launch of Award Winning Xprecia Stride™ Coagulation Analyzer

Siemens Healthcare Diagnostics, Inc. ("Siemens") today announced the full commercial launch of the Xprecia Stride™ Coagulation Analyzer following successful completion of its limited European release. The system will now be marketed through Siemens' extensive sales and distribution network in a growing number of markets, currently excluding the U.S. (which will require FDA 510(k) clearance).

In addition, Siemens has today announced that the Xprecia Stride™ Coagulation Analyzer has been awarded the internationally respected Red Dot Award for Product Design for 2015. The Red Dot Product Design Competition started in Germany in 1954 and its award, the 'Red Dot,' is an internationally recognised quality seal. See www.red-dot.org for further details on the Red Dot competition and the award.

The Xprecia Stride™ Coagulation Analyzer delivers hand-held Prothrombin time testing (PT/INR) for point-of-care monitoring and management of the oral anticoagulation therapy (OAT), Warfarin. The product was specifically designed to meet the growing demand for fast and reliable PT/INR results in physician offices and walk-in clinics to help healthcare professionals make informed decisions about patient care. Universal Biosensors will be the manufacturer of PT/INR strips for Siemens at the Company's plant in Rowville, Victoria.

"The Xprecia Stride™ Coagulation Analyzer is among the most radical, user-friendly redesigns of a point-of-care coagulation analyzer since they became widely available more than 20 years ago. This analyzer includes a number of innovations and features not found on most other point-of-care analyzers," said David Stein, Ph.D., CEO of Siemens Diagnostics Point of Care Business Unit.

A copy of the press release by Siemens is attached.

UBI CEO Paul Wright said: *"We are thrilled that the limited release has gone well and that Siemens will now be rolling out the Xprecia Stride™ Coagulation Analyzer. The Red Dot Award is a clear validation of the product's unique features that will deliver real benefits to patients and healthcare professionals."*

The limited European release of the Xprecia Stride™ Coagulation Analyzer was initiated in December 2014.

Patients using Warfarin require frequent testing to assess the clotting tendency of their blood. The Prothrombin time (PT/INR) test allows physicians to adjust patient doses for diet and lifestyle changes. The worldwide point-of-care coagulation testing market was estimated at about US\$1 billion in 2014 and is forecast to grow by about 9% per annum to about US\$1.4 billion by 2018. The point-of-care coagulation testing market is dominated by PT/INR testing, which represents about 65% of this market.

Ends

Universal Biosensors Inc
ARBN 121 559 993

1 Corporate Avenue
Rowville VIC 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

Enquiries:

Mr Paul Wright: 03 9213 9000

About Universal Biosensors

For additional information in relation to Universal Biosensors, refer to
<http://www.universalbiosensors.com>.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposed offering will occur, and the terms of any such offering are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.

Tarrytown, NY, May 13, 2015

Siemens Healthcare Diagnostics launches Xprecia Stride Coagulation Analyzer

- **A truly handheld portable analyzer for any point-of-care setting**
- **Features such as barcoded results, hands-free strip disposal and ease of navigation promote safety, accuracy and ease-of-use**

Building on more than 30 years of central lab hemostasis leadership, Siemens Healthcare Diagnostics is introducing a first-of-its-kind, hand-held portable coagulation analyzer. The Xprecia Stride Coagulation Analyzer¹ delivers fast, reliable Prothrombin time testing (PT/INR) for point-of-care monitoring and management of oral anticoagulation therapy (OAT) with warfarin, a vitamin K antagonist.

More than 800 million PT/INR tests will be administered world-wide this year² as part of therapy monitoring for patients with a host of conditions, including atrial fibrillation, open and minimally invasive heart valve replacement, deep vein thrombosis, and congenital heart defects, among others. The Xprecia Stride Coagulation Analyzer was specifically designed to meet the growing demand for fast and reliable PT/INR results in physician offices and walk-in clinics to help healthcare professionals make informed decisions about patient care.

“Unlike our previous coagulation point-of-care analyzer, the Xprecia Stride analyzer does not place any limits on us as to the kinds of patients that can be tested,” said Hematologist Dr. Maria Labrador of Hospital Cruz Roja in Cordoba, Spain, where the Xprecia Stride analyzer is currently being used to test patients on a daily basis. “We test around 50 patients a day for PT/INR using the Xprecia Stride analyzer and we have been happy with the results from the very beginning.”

Winner of the internationally respected Red Dot Award: Product Design for 2015,

the analyzer includes a number of innovations and features not found on most other point-of-care analyzers. No bigger than a large screen smartphone and weighing just 300g, the Xprecia Stride Coagulation Analyzer can be held at any angle and brought directly to the patient's finger for efficient and comfortable blood sample application.

"The Xprecia Stride Coagulation Analyzer is among the most radical, user-friendly redesigns of a point-of-care coagulation analyzer since they became widely available more than 20 years ago," said David Stein, Ph.D., CEO of Siemens Diagnostics Point of Care Business Unit. "Our analyzer is designed to be safer, more efficient and more ergonomically friendly than the products available today. The Xprecia Stride Analyzer uses simple icons and animation in a color display more commonly found in smartphones than medical instruments. Receiving the Red Dot award validates this unique product design and reinforces our efforts to bring a highly usable, lab-accurate coagulation analyzer to the point of care."

To help increase workflow efficiency and usability, an integrated bar-code scanner simplifies data capture for accurate calibration of new lot numbers prior to testing.

The Xprecia Stride analyzer uses fresh capillary (finger stick) whole blood and results are expressed in PT seconds or as a PT/INR (international normalized ratio). It utilizes the same Dade® Innovin® reagent used by Siemens central lab analyzers to minimize any potential for variability. Studies have shown the performance to be equivalent to a reference laboratory hemostasis system³, with results available within minutes.

Safety features include a first-of-its kind spring-loaded test strip eject button that allows the user to eject a used test strip and easily dispose of it without touching it, minimizing any potential biohazard exposure.

Other features include easy data transfer to a computer; color display and animated step-by-step instructions to help guide the user during testing. When taken together, all of these innovations become more important as the use of point-of-care PT/INR testing becomes critical to a growing number of procedures and treatments that utilize anticoagulation therapy.

1. Not available for sale in the U.S.
2. Jackson CM, and Esnouf MP. Clin, Chem, 2005;51(3):483-485
3. White Paper, Fernando R., Jacobson AK, Kenneday S., Scribner A, "PT/INR Test Performance of the Xprecia Stride Coagulation Analyzer on Capillary Blood,"; Siemens Healthcare Diagnostics, Inc

For further information on Xprecia Stride Coagulation Analyzer, please visit:

www.siemens.com/xprecia

Contact for journalists:

Siemens Healthcare, Media and Public Relations

John Gillespie, phone: +1 914-524-2636

E-mail: john.gillespie@siemens.com

Follow us on Twitter at: www.twitter.com/siemenshealth

The products/features (here mentioned) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Further details are available from the local Siemens organizations.

Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of combined cycle turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2014, which ended on September 30, 2014, Siemens generated revenue from continuing operations of €71.9 billion and net income of €5.5 billion. At the end of September 2014, the company had around 357,000 employees worldwide. Further information is available on the Internet at <http://www.siemens.com>.